Kelly C. Hewitt
No Rating Available
(Learn About Our Rating System)

Kelly C. Hewitt, MD, FACS

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

2K, Breast Oncology
Salt Lake City
801-587-4241

South Jordan Health Center

South Jordan
801-213-4500

  • Kelly Hewitt, MD, FACS, is a breast surgical oncologist at University of Utah Health and Huntsman Cancer Institute specializing in the surgical care of malignant and benign breast disease and management and surgical care of ductal carcinoma in situ (DCIS).

    Dr. Hewitt received her undergraduate degree from Johns Hopkins University and went to Georgetown University for her medical degree. She then completed her surgical residency at the University of Utah and received fellowship training in breast surgical oncology at the University of California, San Francisco.

    Dr. Hewitt’s research interests include minimizing overdiagnosis and overtreatment of DCIS and investigating ways to understand which patients require surgery and who may be managed with active surveillance. She is also involved in clinical trials for early-stage breast cancer and improving access to care throughout the Mountain West. She is a national co-principal investigator for the DCIS:RECAST clinical trial.

    Dr. Hewitt strives to provide personalized surgical care by working closely with her patients. She helps them understand their condition and treatment options, collaborating to create a surgical plan that aligns with their personal goals while ensuring optimal care for their disease.

    In her free time, Dr. Hewitt enjoys trail running, mountain biking, snowboarding, curling up on the couch with a good book, and attending her kids’ activities.

    Specialties

    Board Certification

    American Board of Surgery

  • Kelly Hewitt, MD, FACS, is a breast surgical oncologist at University of Utah Health and Huntsman Cancer Institute specializing in the surgical care of malignant and benign breast disease and management and surgical care of ductal carcinoma in situ (DCIS).

    Dr. Hewitt received her undergraduate degree from Johns Hopkins University and went to Georgetown University for her medical degree. She then completed her surgical residency at the University of Utah and received fellowship training in breast surgical oncology at the University of California, San Francisco.

    Dr. Hewitt’s research interests include minimizing overdiagnosis and overtreatment of DCIS and investigating ways to understand which patients require surgery and who may be managed with active surveillance. She is also involved in clinical trials for early-stage breast cancer and improving access to care throughout the Mountain West. She is a national co-principal investigator for the DCIS:RECAST clinical trial.

    Dr. Hewitt strives to provide personalized surgical care by working closely with her patients. She helps them understand their condition and treatment options, collaborating to create a surgical plan that aligns with their personal goals while ensuring optimal care for their disease.

    In her free time, Dr. Hewitt enjoys trail running, mountain biking, snowboarding, curling up on the couch with a good book, and attending her kids’ activities.

    Board Certification and Academic Information

    Academic Departments Surgery -Primary
    Academic Divisions Surgical Oncology
    Board Certification
    American Board of Surgery

    Education history

    Fellowship Breast Surgical Oncology - University of California, San Francisco School of Medicine Fellow
    Residency General Surgery - University of Utah School of Medicine Resident
    Professional Medical Medicine - Georgetown University School of Medicine M.D.
    Undergraduate Biology - Johns Hopkins University B.A.

    Selected Publications

    Journal Article

    1. Kuo MC, Sims J, Solis OK, Meszoely IM, Sweeting RS, Grau AM, Hewitt KC, Kauffmann RM, Kelley MC, McCaffrey RL (2024). Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ. Breast Cancer Res Treat. (Read full article)
    2. Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, ISPY2 Locoregional Working Group, Boughey JC (2024). ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy-Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. (Read full article)
    3. Sols O, Addae J, Sweeting R, Meszoely I, Grau A, Kauffmann R, Kelley M, McCaffrey R, Hewitt K (2024). Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ. Breast Cancer Res Treat. (Read full article)
    4. Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, ISPY2 Locoregional Working Group (2024). Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. (Read full article)
    5. Addae JK, Sweeting RS, Meszoely IM, McCaffrey RL, Kauffmann RM, Kelley MC, Grau AM, Hewitt K (2023). Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience. Breast Cancer Res Treat, 204(1), 117-121. (Read full article)
    6. Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA (2023). Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial. Ann Surg Oncol, 30(11), 6401-6410. (Read full article)
    7. Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA (2021). Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies. Am J Surg, 223(4), 699-704. (Read full article)
    8. Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA (2020). Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience. Ann Surg Oncol, 28(5), 2555-2560. (Read full article)
    9. Hewitt K, Son J, Glencer A, Borowsky AD, Cooperberg MR, Esserman LJ (2020). The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. Cancer Epidemiol Biomarkers Prev, 29(12), 2463-2474. (Read full article)
    10. Hewitt K, Lin H, Faraklas I, Morris S, Cochran A, Saffle J (2013). Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections. J Burn Care Res, 35(2), e106-11. (Read full article)
    11. Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill SJ (2013). Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure. HPB (Oxford), 16(1), 62-9. (Read full article)

    Letter

    1. Scaife CL, Hewitt K, Sheng X, Russell KW, Mone MC (2015). Reply: Should we operate for an intraabdominal emergency in the setting of disseminated cancer? [Letter to the editor]. Surgery, 159(3), 981-3. (Read full article)
    2. Scaife CL, Hewitt K, Sheng X, Russell KW, Mone MC (2015). Should we operate for an intra-abdominal emergency in the setting of disseminated cancer? [Letter to the editor]. Surgery, 158(3), 636-45. (Read full article)